# US 2022/0036993 A1 · Pexidartinib risk evaluation and mitigation strategy (rems)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0036993 A1
- Document ID: US20220036993A1
- Status: Published application
- Kind: A1
- Application number: 17/390,217
- Filed: 2021-07-30
- Published: 2022-02-03
- Earliest claimed: 2020-07-31
- Assignees: Daiichi Sankyo Company, Limited
- Applicants: Daiichi Sankyo Company, Limited
- Inventors: Dale Edward SHUSTER; Hamim ZAHIR; Ophelia Qiping YIN; Leonidas Daniel DROGARIS; Vikram Jeet DEV; Laurie DELEVE; James Hendricks LEWIS
- Web page: https://patentgrep.com/patent/US20220036993A1

## CPC

- G16H 20/17: delivered via infusion or injection
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/30: for calculating health indices; for individual health risk assessment
- A61B 2503/42: for laboratory research
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates generally to methods for using pexidartinib and related Risk Evaluation and Mitigation Strategy (REMS), while reducing the occurrence of hepatotoxic adverse events.

## Claims

### Claim 1

A method comprising:
receiving, by at least one computing device, data encapsulating a request to fill a prescription for pexidartinib, or a pharmaceutically acceptable salt thereof, for a patient, the request specifying a pharmacy initiating the request and including an identification of the patient;
polling a server with the pharmacy identification and the patient identification to determine whether
(i) the pharmacy is registered and pre-approved to fill prescriptions for pexidartinib, or a pharmaceutically acceptable salt thereof;
(ii) the patient executed a consent form or other acknowledgement associated with the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, and
(iii) the patient has a patient status form prepared by a prescribing entity transmitted or prepared within a corresponding validity window thereby making such patient status form active, the validity windows increasing in length of days as treatment of the patient with pexidartinib, or a pharmaceutically acceptable salt thereof, progresses;
transmitting data responsive to the request approving filling of the prescription by the pharmacy if it is determined that the pharmacy is registered and pre-approved to fill prescriptions for pexidartinib, or a pharmaceutically acceptable salt thereof, the patient has executed the consent form or other acknowledgment, and the patient has an active patient status form; and
transmitting data responsive to the request rejecting filling of the prescription by the pharmacy if it is determined (a) that the pharmacy is not registered and pre-approved to fill prescriptions for pexidartinib, or a pharmaceutically acceptable salt thereof, (b) the patient has executed the form, or (c) the patient does not have an active patient status form.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient status form encapsulates data regarding at least one liver function test performed by the patient prior to and/or after commencement of treatment.

### Claim 3 (depends on 2)

The method of claim 2, wherein the liver function tests are conducted on a frequency of weekly for the first eight weeks of treatment, every two weeks during a third month of treatment, every three months until a first year anniversary of treatment and every six months thereafter.

### Claim 4 (depends on 1)

The method of claim 1, wherein the validity windows has a length equal to one month for months 1 to 3 from a benchmark date, the validity windows have a length equal to three months for months 3 to 12 from the benchmark date, and the validity windows have a length equal to six months after month 12 from the benchmark date.

### Claim 5 (depends on 4)

The method of claim 4, wherein the benchmark date is a date on which the prescription for pexidartinib, or a pharmaceutically acceptable salt thereof, was first shipped to the patient.

### Claim 6 (depends on 4)

The method of claim 4, wherein the benchmark date is a date on which the prescription for pexidartinib, or a pharmaceutically acceptable salt thereof, was first received by the patient by mail.

### Claim 7 (depends on 4)

The method of claim 4, wherein the benchmark date is a date on which the prescription for pexidartinib, or a pharmaceutically acceptable salt thereof, was first received by the patient at pharmacy.

### Claim 8 (depends on 1)

The method of claim 1 further comprising:
determining that a most recent patient status form for the patient is outside a corresponding validity window but within a pre-specified grace period;
transmitting data responsive to the request approving filling of the prescription by the pharmacy if it is determined that the pharmacy is registered and pre-approved to fill prescriptions for pexidartinib, or a pharmaceutically acceptable salt thereof, and the patient has executed the consent form or other acknowledgment.

### Claim 9 (depends on 8)

The method of claim 8, wherein the grace period is twenty (20) days.

### Claim 10 (depends on 8)

The method of claim 8 further comprising:
determining that a most recent patient status form for the patient is outside a corresponding validity window and outside the pre-specified grace period.

### Claim 11 (depends on 10)

The method of claim 10 further comprising:
marking the patient as inactive at the server in response to the determination that a most recent patient status form for the patient is outside the corresponding validity window and outside the pre-specified grace period.

### Claim 12 (depends on 10)

The method of claim 10 further comprising:
transmitting data to the prescribing entity indicating that the patient is overdue for a patient status form and requesting the prescribing entity to submit an updated patient status form.

### Claim 13 (depends on 1)

The method of claim 1 further comprising:
polling the server with an identification of a prescribing entity; and
wherein the request to fill the prescription is approved if the server indicates that the prescribing entity is authorized to fill the prescription and the request to fill the prescription is rejected if the server indicates that the prescribing entity is not authorized to fill the prescription.

### Claim 14 (depends on 1)

The method of claim 1 further comprising:
transmitting data responsive to the request modifying a dosage and/or dosage frequency based on the patient status form.

### Claim 15 (depends on 1)

The method of claim 1, wherein the server is a risk evaluation and mitigation strategies (REMS) server having an associated database storing patient, prescribing entity, and pharmacy information.

### Claim 16 (depends on 15)

The method of claim 15 further comprising:
transmitting data to the REMS server to register healthcare providers in the database who have completed a knowledge assessment regarding pexidartinib.

### Claim 17 (depends on 15)

The method of claim 15 further comprising:
transmitting lab work data characterizing liver function of the patient during treatment with pexidartinib, or a pharmaceutically acceptable salt thereof, to the REMS server for storage in the database.

### Claim 18 (depends on 15)

The method of claim 15 further comprising:
transmitting data to the REMS server to register patients in the database.

### Claim 19 (depends on 18)

The method of claim 18, wherein the acknowledgements from the patients comprises an acknowledgment that a patient guide has been reviewed.

### Claim 20 (depends on 16)

The method of claim 16 further comprising:
transmitting data to the REMS server to register pharmacies in the database who have completed a certification program regarding pexidartinib, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20 further comprising:
transmitting a consent form or other acknowledgment to patient requesting a prescription who is not registered in the patient database in response to such request.

### Claim 22 (depends on 1)

The method claim 1 further comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) monitoring the patient by measuring the patient's liver function; and
c) reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 23 (depends on 22)

The method of claim 22, wherein the patient is being treated for symptomatic tenosynovial giant cell tumor (TGCT).

### Claim 24 (depends on 22)

The method of claim 22, wherein the measuring of the patient's liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
i) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
ii) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 26 (depends on 24)

The method of claim 24, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 27 (depends on 24)

The method of claim 24, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 28 (depends on 24)

The method of claim 24, wherein if the ALP level is greater than 2 times the corresponding ULN and the GGT is greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the ALP level is less than or equal to 2 times the corresponding ULN.

### Claim 29 (depends on 24)

The method of claim 24, wherein the measuring of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein if the TB level is greater than the corresponding ULN and less than 2 times the corresponding ULN or the DB level is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the TB or DB level is not less than corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 31 (depends on 29)

The method of claim 29, wherein if the TB level is greater than or equal to 2 times the corresponding ULN or the DB level is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB level is less than or equal to the corresponding ULN.

### Claim 32 (depends on 22)

The method of claim 22, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a cytochrome P450 3A (CYP3A) inhibitor, a uridine diphosphate-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 33 (depends on 22)

The method of claim 22, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 34 (depends on 22)

The method of claim 22, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 35 (depends on 22)

The method of claim 22, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 36 (depends on 25)

The method of claim 25, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 37 (depends on 1)

The method of claim 1 further comprising:
a) registering one or more healthcare providers in a healthcare provider database in a non-transitory computer readable storage medium, wherein the one or more healthcare providers have completed a knowledge assessment regarding pexidartinib;
b) requiring the one or more healthcare providers to assess the patient's baseline liver functions;
c) registering the patient in a database, wherein the patients has reviewed a patient guide and has had a baseline liver function assessed; and
d) during treatment, re-assessing the patient's liver functions and modifying a dose of pexidartinib, or a pharmaceutically acceptable salt thereof, as needed.

### Claim 38 (depends on 37)

The method of claim 37, further comprising registering one or more pharmacies which have completed a certification program regarding pexidartinib, or a pharmaceutically acceptable salt thereof, in a pharmacy database, and wherein the one or more pharmacies only dispense pexidartinib, or a pharmaceutically acceptable salt thereof, to patients who are registered in the patient database.

### Claim 39 (depends on 37)

The method of claim 37, wherein the assessing of the patient's baseline liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 41 (depends on 39)

The method of claim 39, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 42 (depends on 39)

The method of claim 39, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 43 (depends on 39)

The method of claim 39, wherein if the ALP level is greater than 2 times the corresponding ULN with the GGT greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until ALP level is less than or equal to 5 times the corresponding ULN and then
the liver function measurements are conducted weekly until ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 44 (depends on 37)

The method of claim 37, wherein the assessing of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein if TB is greater than the corresponding ULN to less than 2 times the corresponding ULN or DB is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and liver function measurements are conducted twice a week; and
b) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
c) if the TB or DB level is not less than the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 46 (depends on 44)

The method of claim 44, wherein if the TB level is greater or equal to 2 times the corresponding ULN or DB is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB levels is less than or equal to the corresponding ULN.

### Claim 47 (depends on 37)

The method of claim 37, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 48 (depends on 37)

The method of claim 37, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 49 (depends on 37)

The method of claim 37, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 50 (depends on 37)

The method of claim 37, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 51 (depends on 40)

The method of claim 40, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 52 (depends on 1)

The method of claim 1, wherein the patient having symptomatic tenosynovial giant cell tumor (TGCT), the method further comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) monitoring the patient by measuring the patient's liver function; and
c) reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 53 (depends on 52)

The method of claim 52, wherein the measuring of the patient's liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
i) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
ii) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 55 (depends on 53)

The method of claim 53, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 56 (depends on 53)

The method of claim 53, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 57 (depends on 53)

The method of claim 53, wherein if the ALP level is greater than 2 times the corresponding ULN and the GGT is greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 58 (depends on 52)

The method of claim 52, wherein the measuring the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 59 (depends on 58)

The method of claim 58, wherein if the TB level is greater than the corresponding ULN and less than 2 times the corresponding ULN or the DB level is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the TB or DB level is not less than corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 60 (depends on 58)

The method of claim 58, wherein if the TB level is greater than or equal to 2 times the corresponding ULN or the DB level is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB level is less than or equal to the corresponding ULN.

### Claim 61 (depends on 53)

The method of claim 53, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a cytochrome P450 3A (CYP3A) inhibitor, a uridine diphosphate-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 62 (depends on 53)

The method of claim 53, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 63 (depends on 53)

The method of claim 53, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 64 (depends on 53)

The method of claim 53, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in a patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 65 (depends on 54)

The method of claim 54, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 66

A method for treating a patient with pexidartinib, or a pharmaceutically acceptable salt thereof, while minimizing a risk of serious and potentially fatal liver injury, wherein the patient having symptomatic tenosynovial giant cell tumor (TGCT), the method comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) registering one or more healthcare providers in a healthcare provider database in a non-transitory computer readable storage medium, wherein the one or more healthcare providers have completed a knowledge assessment regarding pexidartinib;
c) requiring the one or more healthcare providers to assess the patient's baseline liver functions;
d) registering the patient in a database, wherein the patient has reviewed a patient guide and has had a baseline liver function assessed; and
e) during treatment, re-assessing a patient's liver function and reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 67 (depends on 66)

The method of claim 66, further comprising registering one or more pharmacies which have completed a certification program regarding pexidartinib, or a pharmaceutically acceptable salt thereof, in a pharmacy database, and wherein the pharmacies only dispense pexidartinib, or a pharmaceutically acceptable salt thereof, to patients who are registered in the patient database.

### Claim 68 (depends on 66)

The method of claim 66, wherein the assessing of the patient's baseline liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 69 (depends on 68)

The method of claim 68, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 70 (depends on 68)

The method of claim 68, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 71 (depends on 68)

The method of claim 68, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 72 (depends on 68)

The method of claim 68, wherein if the ALP level is greater than 2 times the corresponding ULN with the GGT greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 73 (depends on 66)

The method of claim 66, wherein the assessing of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 74 (depends on 63)

The method of claim 63, wherein if TB is greater than the corresponding ULN to less than 2 times the corresponding ULN or DB is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and liver function measurements are conducted twice a week; and
b) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
c) if the TB or DB level is not less than the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 75 (depends on 63)

The method of claim 63, wherein if the TB level is greater or equal to 2 times the corresponding ULN or DB is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB levels is less than or equal to the corresponding ULN.

### Claim 76 (depends on 66)

The method of claim 66, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 77 (depends on 66)

The method of claim 66, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 78 (depends on 66)

The method of claim 66, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 79 (depends on 66)

The method of claim 66, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 80 (depends on 69)

The method of claim 69, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 81 (depends on 1)

A system comprising:
at least one data processor; and
memory storing instructions which, when executed by the at least one data processor, implement a method of claim 1.

### Claim 82 (depends on 1)

A non-transitory computer program product comprising instructions which, when executed by at least one computing device, result in a method of claim 1.
